Stock Info (+) Info bourse (+)

TSX: SVA  |  OTCQB: SEOVF
Frankfurt Exchange, Xetra: PSH

Investors Investisseur

Sernova is a regenerative medicine company developing therapeutic technologies with multibillion-dollar market potential for each of its clinical indications. Sernova est une société de médecine régénérative développant des technologies thérapeutiques offrant un potentiel de marché de plusieurs milliards de dollars pour chacune de ses indications cliniques.

Read about Financial Reports, Events, Analyst Coverage and Stock Price. Consultez nos rapports financiers, nos événements, la couverture des analystes et le cours des actions.

 

Investor Presentation Présentation investisseurs

Les documents suivants ne sont présentement disponibles qu’en anglais

Sernova Corporate Presentation - September 2024

September 11, 2024 11 September, 2024

2024 Sernova Annual General Meeting Presentation

May 7, 2024 7 May, 2024

Oppenheimer 34th Annual Healthcare MedTech & Services Conference

March 14, 2024 14 March, 2024
 

News Releases Communiqués de presse

Latest News Releases Derniers communiqués de presse

October 3, 2024 3 October, 2024

Sernova to Present at the 2024 Cell & Gene Meeting on the Mesa

September 19, 2024 19 September, 2024

Sernova Appoints David Paterson Ph.D. to its Board of Directors

September 12, 2024 12 September, 2024

Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

September 5, 2024 5 September, 2024

Sernova to Participate in Upcoming H.C. Wainwright Investor Conference

September 4, 2024 4 September, 2024

Sernova Closes $5.2 Million Over-subscribed Non-brokered, Private Placement

August 29, 2024 29 August, 2024

Sernova Announces Oversubscribed Non-brokered Private Placement

August 20, 2024 20 August, 2024

Sernova Announces Up to $4 Million Private Placement Priced at a Premium

August 15, 2024 15 August, 2024

Lead Investigator for Sernova's Clinical Trial with Cell Pouch for Type 1 Diabetes to Deliver Oral Presentation at the 2024 EASD Annual Meeting

 

Latest Updates Dernières mises à jour

October 5, 2023 5 October, 2023

Sernova Business Update

June 30, 2023 30 June, 2023

Marek Sutherland of CTV News London - Cure for type one diabetes getting closer, London company says

June 30, 2023 30 June, 2023

Noah Stansfield of CGT Live - Patients With T1D Achieve Insulin Independence Following Implantation of Cell Pouch System and Islet Transplant

June 28, 2023 28 June, 2023

Sean Whooley and Danielle Kirsh of Fast Five- Teleflex has a Class I recall, Boston Scientific appoints two new board directors (Sernova discussed in the podcast recording from 1:00-2:58 time marks)

June 26, 2023 26 June, 2023

Lei Lei Wu of EndPoints News - Sernova says five diabetes patients have now been taken off insulin after 'cell pouch' therapy

June 26, 2023 26 June, 2023

Shane Whooley of MassDevice - Sernova reports positive interim data for Cell Pouch System

June 26, 2023 26 June, 2023

Madeleine Armstrong of Evaluate Vantage talks about Sernova - ADA 2023 – Vertex raises hopes of type 1 diabetes cure But it still has a long way to go with its islet cell therapies.

June 26, 2023 26 June, 2023

Shane Whooley of Drug Delivery Business News: A MassDevice Resource - Sernova reports positive interim data for Cell Pouch System

May 5, 2023 5 May, 2023

Marisa Wexler of Hemophilia News Today - AstraZeneca, Sernova join forces on cell therapy research

May 4, 2023 4 May, 2023

Medical Device Network - Sernova and AstraZeneca team to study novel therapeutic cell applications

May 3, 2023 3 May, 2023

Manshi Mamtora of Seeking Alpha - Sernova joins hands with AstraZeneca for potential therapeutic cell applications

May 3, 2023 3 May, 2023

Shane Whooley of Drug Delivery Business - Sernova, AstraZeneca collaborate to deliver therapeutic cells with Sernova Cell Pouch

May 3, 2023 3 May, 2023

Noah Stansfield of CGTLive features Sernova in Around the Helix: Cell and Gene Therapy Company Updates – May 3, 2023

March 17, 2023 17 March, 2023

Dr. Philip Toleikis recently spoke with proto.life (formerly NEO.LIFE) on the advancements of our Cell Pouch System™ to develop a potential ‘functional cure’ to improve the quality of life for patients with T1D

February 8, 2023 8 February, 2023

Dr. Philip Toleikis sat down with PharmaShots to discuss our global strategic partnership with Evotec and how it will contribute to the advancement of our Cell Pouch System as a "functional cure" for insulin-dependent diabetes

January 31, 2023 31 January, 2023

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances

January 9, 2023 9 January, 2023

Sernova Featured at PBA's Year in Review Event

December 20, 2022 20 December, 2022

Jim Cornell of Labiotech.eu - Sernova's Cell Pouch System Tackles Diabetes

November 23, 2022 23 November, 2022

The London Free Press - "London Company Working on Diabetes Cure Ramps Up Hiring as Trials Show Promise"

November 22, 2022 22 November, 2022

Shane Whooley of Mass Device - "How Sernova seeks to treat insulin-dependent diabetes with its Cell Pouch System"

November 16, 2022 16 November, 2022

Sernova's Fireside Chat from the 2022 Stifel Healthcare Conference

November 7, 2022 7 November, 2022

Shane Whooley of Mass Device - "Sernova to enroll second cohort in trial of Cell Pouch System for type 1 diabetes"

October 12, 2022 12 October, 2022

Collaborator, Dr. Alice Tomei from the University of Miami, discussed the advancements in conformal coating to overcome challenges associated with transplanting insulin-producing cells in the body.

October 6, 2022 6 October, 2022

Dr. Philip Toleikis' Fireside Chat with LifeSci Partners at the Virtual HealthTech Symposium

August 18, 2022 18 August, 2022

Dr. Philip Toleikis sat with Erin Harris, Cell & Gene Podcast to discuss the development of the Cell Pouch as a "functional cure" for chronic diseases such as T1D

July 28, 2022 28 July, 2022

Dr. Philip Toleikis sat with Ayesha Rashid on the Xtalks Life Science Podcast to explain how our Cell Pouch System works and the clinical advances we are making to develop a "functional cure" for patients with diabetes

June 27, 2022 27 June, 2022

Dr. Philip Toleikis, shared his thoughts on the next treatment innovations being a "functional cure" for chronic diseases in a recent pharma's almanac roundtable

June 24, 2022 24 June, 2022

Miriam E. Tucker from Medscape highlights the recent presentation of our interim data at the 2022 ADA as well as how our innovative Cell Pouch differs from other developments in the diabetes space

June 21, 2022 21 June, 2022

Sernova featured in Evaluate Vantage: "Sernova gets under the skin"

June 16, 2022 16 June, 2022

Dr. Philip Toleikis joined Stacey Simms on Diabetes Cxns to discuss our Cell Pouch System, a potential "functional cure" for insulin-dependent diabetes.

June 14, 2022 14 June, 2022

Dr. Philip Toleikis was recently interviewed by Joachim Brunner of SmallCap Investor TV

June 9, 2022 9 June, 2022

Dr. Philip Toleikis spoke with Alex Keown from BioSpace about the updated positive interim data from the Phase 1/2 diabetes clinical trial of our Cell Pouch System, presented at the 2022 ADA by our collaborators at the University of Chicago

June 2, 2022 2 June, 2022

Loading... Chargement...

Sernova Opens the Market Thursday, June 2, 2022

February 25, 2022 25 February, 2022

Loading... Chargement...

Sernova Made the 2022 TSX Venture 50 List!

November 18, 2021 18 November, 2021

Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

September 30, 2021 30 September, 2021

Loading... Chargement...

Dr. Tomei Conformal Coating Immunoprotection Webinar with Sernova

April 28, 2021 28 April, 2021

Loading... Chargement...

Sernova KOL Event on Thyroid Disease with Dr. Sam Wiseman

June 29, 2020 29 June, 2020

Loading... Chargement...

Watch our latest commercial!

June 18, 2020 18 June, 2020

Loading... Chargement...

ADA Scientific Sesssions

December 4, 2019 4 December, 2019

Loading... Chargement...

Whiteboard: Sernova's Cell Pouch for Type 1 Diabetes (T1D)

April 23, 2019 23 April, 2019

Loading... Chargement...

CTV London: Hope for diabetes cure

December 28, 2018 28 December, 2018

Loading... Chargement...

New device from Ont. firm could revolutionize diabetes care

June 7, 2018 7 June, 2018

Loading... Chargement...

Watch Dr Philip Toleikis, Ph.D. on CTV News

 

Financial Report and Other Filings Rapport financier et autres dépôts

 

Events Événements

Upcoming Events Évènements à venir

There are no events at this time. Il n'y a pas d'événements pour le moment.


Octoberoctobre 2024

SundayMondayTuesdayWednesdayThursdayFridaySaturday
dimanchelundimardimercredijeudivendredisamedi
SMTWTFS
DLMMJVD

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31


Novembernovembre 2024

SundayMondayTuesdayWednesdayThursdayFridaySaturday
dimanchelundimardimercredijeudivendredisamedi
SMTWTFS
DLMMJVD

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30


 

Analyst Coverage Couverture des analystes

Please Note Notez s'il vous plaît

Sernova and its securities are covered by the following investment firms. This list of investment firms is being provided solely for your information and convenience and does not constitute an endorsement of or concurrence with any information, opinions, estimates, forecasts or recommendations provided by any of the investment firms listed below by Sernova. Furthermore, Sernova does not distribute information or reports prepared by analysts. The following list includes analysts currently known by Sernova Corp. to follow the company but may not be complete or up to date and may change without notice. Sernova undertakes no obligation to update and maintain this list. Please refer to the Legal Notice on this website for further information. Sernova et ses titres font l’objet d’analyse de la part des sociétés d'investissement suivantes. Cette liste de sociétés d'investissement est fournie uniquement à titre informatif et pour votre commodité et ne constitue en aucun cas une approbation ou un accord par Sernova ou ses dirigeants avec les informations, opinions, estimations, prévisions ou recommandations fournies par les sociétés d'investissement énumérées ci-dessous. En outre, Sernova ne distribue pas d'informations ou de rapports préparés par des analystes. La liste suivante inclut les analystes actuellement connus pour suivre la société, mais elle peut ne pas être complete ou à jour et peut changer sans préavis. Sernova n’assume aucune obligation quant à la mise à jour et au maintien de cette liste. Veuillez-vous reporter à l'avis légal sur ce site pour plus d'informations.



Analyst Analyste

Firm Société d’investissement

Phone Téléphone

Andre Uddin, Ph.D

Research Capital Corporation

416.860.8675

Doug Loe

Leede Jones Gable

416.365.9924

Joseph Pantginis, Ph.D

H.C. Wainwright Research

646.975.6968

Rahul Sarugaser & Michael Freeman

Raymond James

416 777 6383 / 416 777 4943

Stefan Quenneville

Echelon Capital Markets

416.662.6134

Tony Butler

Rodman & Renshaw

212 540 4427

 

Stock Price Prix de l'action

Please Note Notez s'il vous plaît

All information is provided "as is" for informational purposes only and is not intended for trading purposes or advice. Neither Sernova nor any independent providers are liable for any errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. Toutes les informations sont fournies "telles quelles" à des fins d'information uniquement, et ne sont pas destinées à des fins transactionnelles ou à titre de conseils ou recommandations. Ni Sernova ni aucun fournisseur indépendant ne peuvent être tenus responsables des erreurs d'information, des données incomplètes, des retards ou des actions prises en fonction des informations contenues dans les presentes.

 

Corporate Governance Gouvernance d'entreprise

Please read the related documents Les documents suivants ne sont présentement disponibles qu’en anglais

Insider Trading Compliance Policy Politique de conformité des opérations d'initiés

PDF file

Whistleblower Policy Politique de dénonciation

PDF file

Constating Documents and Articles Constatation des documents et articles

PDF file

Advance Notice By-law SEDAR filed 2014-04-03 Advance Notice By-law SEDAR filed 2014-04-03s

PDF file

Subscribe to our Newsletter Abonnez-vous à notre newsletter

*indicates required* requis

By subscribing to our Newsletter you will receive Sernova’s press releases and news as they develop by email. We do not send direct mail, customized online advertising, and we do not share your personal information. We respect your privacy. En vous abonnant à notre newsletter, vous recevrez par e-mail les communiqués de presse et les actualités de Sernova au fur et à mesure de leur développement. Nous n'envoyons pas de publipostage, de publicité en ligne personnalisée et nous ne partageons pas vos informations personnelles. Nous respectons votre vie privée.

Please read our Pour plus d’informations, veuillez lire notre Privacy policypolitique de confidentialité.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 03, 2024 3 October, 2024

Sernova to Present at the 2024 Cell & Gene Meeting on the Mesa


LONDON, Ontario; BOSTON, Massachusetts – October 3, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, announced that its CEO, Jonathan Rigby, will be presenting at the 2024 Cell & Gene Meeting on the Mesa being held October 7-9, 2024, at the Arizona Biltmore Hotel in Phoenix, Arizona. The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cell therapy cures.

Mr. Rigby’s presentation is scheduled to begin at 10:00 A.M. MT (12:00 P.M. ET) on Monday, October 7, 2024. The presentation will include updates on Sernova’s type 1 diabetes phase 1/2 clinical trial at the University of Chicago, and its pre-clinical work with Evotec to advance a potential iPSC-based (induced pluripotent stem cell) islet replacement therapy with Sernova’s Cell Pouch™ Transplant System.

ABOUT SERNOVA AND ITS CELL POUCH™ TRANSLPLANT SYSTEM PLATFORM FOR CELL THERAPY

Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead technology, the Cell Pouch Transplant System, a novel implantable and scalable medical device with immune protected therapeutic cells.

On implantation, The Cell Pouch forms a natural, vascularized tissue environment in the body allowing long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in patients with certain chronic diseases. Sernova’s Cell Pouch Transplant System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase I/II clinical study at the University of Chicago.

Sernova partnered with Evotec to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin- producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova’s development pipeline that uses its Cell Pouch Transplant System also includes: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.

FOR FURTHER INFORMATION, PLEASE CONTACT: David Burke VP, Investor Relations Sernova Corp. Tel: +1 917-618-2651 Email: david.burke@sernova.com Website: www.sernova.com

The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 19, 2024 19 September, 2024

Sernova Appoints David Paterson Ph.D. to its Board of Directors


Sernova Appoints David Paterson Ph.D. to its Board of Directors

LONDON, Ontario; BOSTON, Massachusetts – September 19, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, announces today that David Paterson Ph.D. will join Sernova’s Board of Directors effective immediately.

“I am pleased to have been able to attract David’s Paterson’s significant talent to Sernova’s Board of Directors,” said Jonathan Rigby, President and Chief Executive Officer of Sernova. “Mr. Paterson brings more than 30 years of biotech experience with substantial contributions as both a senior executive, Board member and founder of numerous companies with a focus on corporate and business development, intellectual property generation and prosecution and alliance management.”

Mr. Paterson is currently employed at Colorado State University as Assistant Vice President for Research Translation and Commercialization where he manages strategic industry relationships. In addition, he brings broad biopharma industry knowledge having worked for Impax Laboratories (IPXL: NASDAQ) in both Europe and North America where he provided leadership and Board support to the business development team for ten years until its acquisition by Amneal Pharmaceuticals (AMRX: NASDAQ). Prior to Impax, Mr. Paterson held senior roles with Sepracor (Sunovion), GlaxoSmithKline and Skyepharma. Mr. Paterson is also a co-founder of Neurogastrx, Inc helping to bring in early-stage capital. Mr. Paterson has a Batchelor of Science from the University of Glasgow, a Ph.D. from the University of Illinois and was a Post-Doctoral Fellow in Molecular Genetics and Cellular Biology at the University of Chicago.

“I am very excited to be joining the Board of Sernova and offer up my scope of expertise to help the company grow and prosper within the type 1 diabetes space and to help open doors to new collaborations and further establish the Cell Pouch Transplantation System as a top tier technology within the Regenerative Medicine Cell Therapy sector,” said David Paterson.

ABOUT SERNOVA AND ITS CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY

Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells.

On implantation, The Cell Pouch forms a natural vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago.

Sernova partnered with Evotec to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin- producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova’s development pipeline that uses its Cell Pouch System also includes: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Christopher Barnes VP, Investor Relations Sernova Corp. Tel: +1 519-902-7923 Email: christopher.barnes@sernova.com Website: www.sernova.com

The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 12, 2024 12 September, 2024

Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function


Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

- Abundant, richly vascularized and functioning islets observed throughout all chambers of Sernova’s Cell Pouch more than 5 years after islet transplantation

- Histological data confirmation of healthy beta, alpha and delta cells secreting insulin, glucagon, and somatostatin in all Cell Pouch Chambers

- Sernova’s Cell Pouch safely contains its therapeutic cells and provides full retrievability using conventional instruments and methods

- Pathology confirmed no evidence of detrimental fibrotic tissue associated with Cell Pouch more than 5 years after implantation

LONDON, Ontario; BOSTON, Massachusetts – September 12, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases today announced the presentation of new positive interim data from the ongoing Phase I/II clinical trial evaluating the safety, tolerability, and efficacy of the Sernova Cell Pouch Transplant System containing donor islets in people living with type 1 diabetes (T1D).

The data was presented by Piotr Witkowski, M.D., Ph.D., Professor of Surgery and Director of the Pancreatic and Islet Transplant Program at University of Chicago Medicine, who is the Lead Investigator for the study, during an oral session at the 2024 European Association for the Study of Diabetes (EASD) Annual Meeting in Madrid, Spain.

All 6 of the patients enrolled in Cohort A of Sernova’s Phase I/II clinical trial with Cell Pouch and donor islets achieved sustained insulin independence after combined islet transplantation into Cell Pouch and intraportally. The first patient to be treated in the trial experienced sustained insulin independence for more than 4 years accompanied by blood sugar levels in the non-diabetic range (HbA1c ≤6.5%). More than 5 years after the first islet transplant, the patient’s Cell Pouches containing the transplanted islets were removed because immune suppression had to be stopped when that patient developed other, nondiabetic health issues not related to Cell Pouch or transplanted islets.

The new histological data from those explanted Cell Pouches confirmed abundant, well-vascularized, functioning islets consisting of cells producing insulin, glucagon and somatostatin, throughout all chambers, more than 5 years after being transplanted to Cell Pouch. Additionally, after being in the body for more than 5 years, a pathology examination confirmed there was no evidence of detrimental fibrotic tissue, material degradation or changes in the architecture of the Sernova Cell Pouch.

“I am excited to see this evidence of well-vascularized and healthy islets 5 years after transplant to Sernova’s Cell Pouch; these interim findings are very promising,” commented Piotr Witkowski M.D., Ph.D. “This is a major step forward in the development of a contained and retrievable cell therapy for the treatment of T1D. This is the first evidence that I am aware of that demonstrates this level of healthy islet survival and function in an implantable and retrievable system for such a long duration.”

“We believe this first-in-world data is significant for Sernova and, more specifically, provides tangible hope for T1D patients that we are a significant step further in our mission of providing a functional cure for this terrible disease; as a Type 1 diabetic myself I could not be more determined to drive our program forward and ultimately onto the market,” said Jonathan Rigby, President and CEO of Sernova. “We look forward to completing Cohort B in the near term and, based on positive data generated thus far, initiating Cohort C of our ongoing trial later this year with an optimized immune suppression regimen. Lastly, we continue to work with our partner Evotec on the development of induced pluripotent stem cell (iPSC)-derived islet-like clusters, which will provide a scalable cell source so that one day we can give patients with T1D their lives back”

ABOUT THE PHASE I/II TRIAL

The Phase I/II trial (NCT03513939) is a U.S. prospective, single-arm, multi-cohort study evaluating the safety, tolerability, and efficacy of Sernova’s Cell Pouch in combination with transplanted human-donor islets in people living with type 1 diabetes (T1D). The trial includes participants aged 18-65 with T1D who experience hypoglycemic unawareness and severe hypoglycemic episodes, and who are eligible for donor islet transplantation. The trial is currently divided into two cohorts. Cohort A involved six patients who received the first-generation 8-channel Cell Pouch. Cohort B is evaluating seven patients transplanted with an optimized 10- channel Cell Pouch, which has a 50% greater islet capacity than the Cell Pouch used in Cohort A. As part of the process, patients are implanted with the Cell Pouch subcutaneously. Approximately six weeks later - allowing time to establish a stable immunosuppression therapy for the patient - islets are transplanted into the prevascularized tissue chambers formed by the Cell Pouch. Safety and efficacy are assessed throughout the 12 months following the last islet transplant. Patients still dependent on insulin 6 months after the second islet transplant may qualify for a third transplant via the portal vein. Those who retain implants will be followed for at least three years. The secondary objectives of the trial include the following efficacy endpoints: continuous glucose monitoring, production of C-peptide, insulin use, HbA1c levels, and the frequency of severe hypoglycemic episodes.

ABOUT SERNOVA AND ITS CELL POUCH™ TRANSPLANT SYSTEM PLATFORM FOR CELL THERAPY

Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead technology, the Cell Pouch Transplant System, a novel implantable and scalable medical device with immune protected therapeutic cells.

On implantation, The Cell Pouch forms a natural, vascularized tissue environment in the body allowing long- term survival and function of therapeutic cells that release essential factors that are absent or deficient in patients with certain chronic diseases. Sernova’s Cell Pouch Transplant System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase I/II clinical study at the University of Chicago.

Sernova partnered with Evotec to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin- producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova’s development pipeline that uses its Cell Pouch Transplant System also includes: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Christopher Barnes VP, Investor Relations Sernova Corp. Tel: +1 519-902-7923 Email: christopher.barnes@sernova.com Website: www.sernova.com The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 05, 2024 5 September, 2024

Sernova to Participate in Upcoming H.C. Wainwright Investor Conference


Sernova to Participate in Upcoming H.C. Wainwright Investor Conference

LONDON, Ontario – September 5, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical- stage company and leader in cell therapeutics, today announced it will be participating in the upcoming H.C. Wainwright 26th Annual Global Investment Conference being held September 9 to 11, 2024 in New York City at the Lotte New York Palace. Company management will also be participating in one-on- one investor meetings at the conference.

Sernova’s presentation will be webcast, details as follows:

Sernova Corporate Presentation Date & Time: 11:00AM ET, September 11, 2024 presented by Jonathan Rigby, President & Chief Executive Officer, Sernova Corp Location:

https://journey.ct.events/view/c4b9e5c3-766e-4c11-a345-bedcacb42ce8

Please contact your representative at H.C. Wainwright to schedule a one-on-one meeting with the management team during the conference.

ABOUT SERNOVA AND ITS CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY

Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes and thyroid disease. Sernova is currently focused on developing a ‘functional cure’ for insulindependent diabetes with its lead technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. On implantation, The Cell Pouch forms a natural, vascularized tissue environment in the body allowing long- term survival and function of therapeutic cells that release essential factors that are absent or deficient in patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago. Sernova is collaborating with Evotec to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership is expected to provide Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova’s Cell Pouch System development pipeline also includes a cell therapy for hypothyroid disease resulting from thyroid gland removal, and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Christopher Barnes VP Investor Relations Sernova Corp. Tel: +1 519-902-7923 Email: christopher.barnes@sernova.com Website: www.sernova.com The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forwardlooking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and/or licensing arrangements on reasonable terms, or at all; conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; obtain all necessary regulatory approvals, or on a timely basis; in-license additional complementary technologies; execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 04, 2024 4 September, 2024

Sernova Closes $5.2 Million Over-subscribed Non-brokered, Private Placement


SERNOVA CLOSES $5.2 MILLION OVER-SUBSCRIBED NON-BROKERED, PRIVATE PLACEMENT

LONDON, ONTARIO – September 4, 2024 - Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it has closed its non-brokered, private placement in the amount over $5.2 million, which includes over-subscriptions of more than $1.2 million.

All securities issued pursuant to the private placement are subject to a hold period of four months under applicable provincial securities laws in Canada. The private placement was announced on August 20, 2024, and closed on September 3, 2024.

On Thursday September 12 at the 2024 EASD Annual Meeting in Madrid, Spain, Sernova’s principal clinical study investigator will provide an update on recent data generated from its phase I/II clinical study of Cell Pouch™ containing human donor islets for the treatment of type 1 diabetes.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

ABOUT SERNOVA AND ITS CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY

Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes and thyroid disease. Sernova is currently focused on developing a ‘functional cure’ for insulindependent diabetes with its lead technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells.

On implantation, The Cell Pouch forms a natural, vascularized tissue environment in the body allowing long- term survival and function of therapeutic cells that release essential factors that are absent or deficient in patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago.

Sernova is collaborating with Evotec to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership is expected to provide Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova’s Cell Pouch System development pipeline also includes a cell therapy for hypothyroid disease resulting from thyroid gland removal, and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Christopher Barnes VP Investor Relations Sernova Corp. Tel: +1 519-902-7923 Email: christopher.barnes@sernova.com Website: www.sernova.com The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forwardlooking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and/or licensing arrangements on reasonable terms, or at all; conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; obtain all necessary regulatory approvals, or on a timely basis; in-license additional complementary technologies; execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - August 29, 2024 29 August, 2024

Sernova Announces Oversubscribed Non-brokered Private Placement


SERNOVA ANNOUNCES OVERSUBSCRIBED NON-BROKERED PRIVATE PLACEMENT

THIS NEWS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

LONDON, ONTARIO - August 29, 2024 - Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that its non-brokered, private placement offering of $4M is oversubscribed with $4.7M of binding agreements received. The closing will occur on Tuesday September 3, 2024, subject to TSX approval.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

ABOUT SERNOVA AND ITS CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY

Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes and thyroid disease. Sernova is currently focused on developing a ‘functional cure’ for insulindependent diabetes with its lead technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. On implantation, The Cell Pouch forms a natural, vascularized tissue environment in the body allowing long- term survival and function of therapeutic cells that release essential factors that are absent or deficient in patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago. Sernova partnered with Evotec to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova’s development pipeline that uses its Cell Pouch System also includes: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Christopher Barnes VP Investor Relations Sernova Corp. Tel: +1 519-902-7923 Email: christopher.barnes@sernova.com Website: www.sernova.com The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forwardlooking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to complete the Offering, in part or at all; secure additional financing and/or licensing arrangements on reasonable terms, or at all; conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; obtain all necessary regulatory approvals, or on a timely basis; in-license additional complementary technologies; execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - August 20, 2024 20 August, 2024

Sernova Announces Up to $4 Million Private Placement Priced at a Premium


Sernova Announces Up to $4 Million Private Placement Priced at a Premium

THIS NEWS RELEASE IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

LONDON, ONTARIO - August 20, 2024 - Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that the Company has secured over $2 million in lead orders in connection with a non-brokered private placement offering (the “Offering”) for up to $4 million units priced at a premium to the market.

Each unit is priced at $0.25, and consists of one common share and one warrant. Each warrant is priced at $0.30 per share and is exercisable for a period of 18 months, subject to Sernova’s option to shorten the exercise period if the 20-day volume-weighted average price of the Company’s shares exceeds $0.50.

The net proceeds from the private placement will be used to continue enrolment in the Company's US-based Phase I/II Type 1 diabetes clinical trial, to advance an IND filing for its post-operative hypothyroidism program and for general corporate purposes.

Newly appointed Sernova CEO Jonathan Rigby stated, “We are pleased to announce a financing round led by legacy investors with insider participation. Our goal is to secure sufficient capital to maintain ongoing clinical initiatives. The company recently announced that data from its ongoing clinical trial of its Cell Pouch™ technology containing donor Islet cells to treat Type 1 diabetes will be presented at the European Association for the Study of Diabetes (EASD), 9-13 September in Madrid, Spain.”

All securities issued in connection with the private placement will be subject to a statutory hold period of four months. Completion of the private placement is subject to customary closing conditions, including acceptance of the TSX. The private placement is expected to close prior to August 28, 2024.

The Company expects insider participation in the Offering, which may be considered a related party transaction within the meaning of Multilateral Instrument 61-101 (“MI 61-101”). Sernova intends to rely on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in Sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of any insider participation.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

ABOUT SERNOVA AND ITS CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY

Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes and thyroid disease. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells.

On implantation, The Cell Pouch forms a natural, vascularized tissue environment in the body allowing long- term survival and function of therapeutic cells that release essential factors that are absent or deficient in patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago.

Sernova partnered with Evotec to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin- producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova’s development pipeline that uses its Cell Pouch System also includes: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A

FOR FURTHER INFORMATION, PLEASE CONTACT:

Christopher Barnes VP Investor Relations Sernova Corp. Tel: +1 519-902-7923 Email: christopher.barnes@sernova.com Website: www.sernova.com

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to complete the Offering, in part or at all; secure additional financing and/or licensing arrangements on reasonable terms, or at all; conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; obtain all necessary regulatory approvals, or on a timely basis; in-license additional complementary technologies; execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - August 15, 2024 15 August, 2024

Lead Investigator for Sernova's Clinical Trial with Cell Pouch for Type 1 Diabetes to Deliver Oral Presentation at the 2024 EASD Annual Meeting


Lead Investigator for Sernova’s Clinical Trial with Cell Pouch for Type 1 Diabetes to Deliver Oral Presentation at the 2024 EASD Annual Meeting

- Dr. Piotr Witkowski MD PhD, Professor of Surgery and Director of the Pancreatic and Islet Transplant Program, and his islet transplant team at University of Chicago Medicine authored an abstract that will be presented, including new data from the ongoing Phase I/II clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D).

LONDON, Ontario; BOSTON, Massachusetts – August 15, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases such as Type 1 Diabetes, today announced a short oral presentation at the upcoming European Association for the Study of Diabetes (EASD) taking place September 9-13, 2024 in Madrid, Spain.

Additional details, including accepted abstracts, are available on the EASD website at www.easd.org In alignment with the embargo policy, Sernova plans to share details from Dr. Witkowski’s talk, following the presentation.

Presentation details:

European Association for the Study of Diabetes - 2024 Annual Meeting – Madrid, Spain Oral Event F: Improving Islet Transplantation - Thursday September 12, 2024 2:00pm to 3:00pm Central European Time

Abstract # 447: Islet allotransplantation into pre-vascularized Sernova Cell Pouch™: Interim Results: P. Witkowski, N. Wojcik, S. Gondek, J. Tomecki, K. Milejczyk, B. Juengel, L. Wang, J. J. Fung, R. Barth, USA.

Sernova Corp continues to collaborate closely with leading academic, pharmaceutical and clinical institutions to expand the scope and impact of its technology. The company anticipates further advancements as it progresses through additional cohorts and trials, with the ultimate goal of offering a scalable solution for insulin-dependent diabetes plus other chronic diseases.

ABOUT SERNOVA AND ITS CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY

Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells.

On implantation, The Cell Pouch forms a natural, vascularized tissue environment in the body allowing long- term survival and function of therapeutic cells that release essential factors that are absent or deficient in patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago.

Sernova partnered with Evotec to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin- producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova’s development pipeline that uses its Cell Pouch System also includes: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Christopher Barnes VP, Investor Relations Sernova Corp. Tel: +1 519-902-7923 Email: christopher.barnes@sernova.com Website: www.sernova.com

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute “forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management’s beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova’s actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Disclaimer Avis de non-responsabilite

Sernova maintains the investor relations section of this internet site as an informational service and for the readers. Sernova maintient la section des relations investisseurs de ce site Internet en tant que service afin d’informer les lecteurs.

This site is not intended to supplement or substitute for the legal disclosure for the Corporation or the prospectus disclosure related to the public offering of any of its securities. Please read the legal notice on the site before you proceed. Ce site n'a pas pour objet de compléter ou de remplacer la divulgation légale de la Société ou les informations du prospectus relatives à l’offre au public de ses titres. Veuillez lire l'avis juridique sur le site avant de poursuivre.


Privacy PolicyPolitique de confidentialité

Updated July 6, 2018

Please read this Policy carefully along with our Legal Notice that describes our Terms of Use for the Website.

By accessing www.sernova.com (the “Website”) you hereby agree with the practices described in this Privacy Policy (the “Policy”)

This Policy applies to all information gathered through the Website and/or any related marketing technique or events.



Information Collection

The information collected is limited to the information that you decide to share with us through the News Dispatch Service, when participating at event or activities or in the general course of business by expressing an interest in obtaining information about Sernova Corp. and our products, such as name, email, phone number, and similar contact information. This information is stored through MailChimp (please refer to MailChimp Privacy Policy at https://mailchimp.com/legal/privacy/).



Information Sharing

Sernova Corp. is the sole owner of any information collected on the Website. We do not sell, share or rent this information to others.



Traffic and Automatic Information Collection

Sernova Corp. maintains log files of the traffic on www.sernova.com. This information is not linked to any personal information that you have provided us. Logs are used to manage traffic, identify content accessed, and IT requirements. Information logged and automatically collected includes without being limited to IP addresses and browser types. This information does not reveal your specific identity.



Cookies

Cookies can be used to provide you with a more personalized experience. The Website may use cookies to make that experience more companionable when you return to the Website. You have the option at all time to decline the use of cookies. If you choose to do so, you may not be able to fully use all features of the Website. You can also delete cookie files at all time from your computer. Those cookies may include first-party cookies (such as the Google Analytics cookies).



Updates

This Policy is a living document and may be amended or updated from time to time without further notice. We encourage you to review the Policy periodically.



Contact

If you have any questions or comments about our policy, you can email us at info@sernova.com or by phone at 1(877) 299-4603 or by mail at

Sernova Corp.
700 Collip Circle, Suite 114
London, ON Canada N6G 4X8

Mis à jour le 6 juillet 2018

Veuillez lire attentivement cette politique ainsi que notre avis juridique qui décrit nos conditions d'utilisation du site Web.

En accédant à www.sernova.com (le «site Web»), vous acceptez les pratiques décrites dans la présente politique de confidentialité (la «politique»).

Cette politique s'applique à toutes les informations collectées via le site Web et / ou toute technique ou événement marketing associé.



Collecte d'informations

Les informations collectées se limitent aux informations que vous décidez de partager avec nous par le biais du service d’expédition de nouvelles, lorsque vous participez à un événement ou à des activités ou que vous vous intéressez à obtenir des informations sur Sernova Corp. comme nom, email, numéro de téléphone et informations de contact similaires. Ces informations sont stockées via MailChimp (veuillez vous reporter aux règles de confidentialité de MailChimp sur https://mailchimp.com/legal/privacy/).



Partage d'information

Sernova Corp. est l'unique propriétaire de toute information collectée sur le site Web. Nous ne vendons pas, ne partageons pas ou ne louons pas ces informations à des tiers.



Collecte d'informations routières et automatiques

Sernova Corp. gère les fichiers journaux du trafic sur www.sernova.com. Ces informations ne sont liées à aucune information personnelle que vous nous avez fournie. Les journaux sont utilisés pour gérer le trafic, identifier le contenu accédé et les besoins informatiques. Les informations consignées et collectées automatiquement ne sont pas limitées aux adresses IP et aux types de navigateur. Cette information ne révèle pas votre identité spécifique.



Cookies

Les cookies peuvent être utilisés pour vous offrir une expérience plus personnalisée. Le site Web peut utiliser des cookies pour rendre cette expérience plus conviviale lorsque vous revenez sur le site Web. Vous avez la possibilité à tout moment de refuser l'utilisation de cookies. Si vous choisissez de le faire, vous ne pourrez peut-être pas utiliser toutes les fonctionnalités du site Web. Vous pouvez également supprimer des fichiers de cookies à tout moment depuis votre ordinateur. Ces cookies peuvent inclure des cookies de première partie (tels que les cookies de Google Analytics).



Mises à jour

Cette politique est un document évolutif et peut être modifié ou mis à jour de temps à autre sans préavis. Nous vous encourageons à consulter la politique périodiquement.



Contact

Si vous avez des questions ou des commentaires sur notre politique, vous pouvez nous envoyer un courriel à info@sernova.com ou par téléphone au 1 (877) 299-4603 ou par courrier à

Sernova Corp.
700 Collip Circle, Suite 114
London, ON Canada N6G 4X8